← Back to Directory

Heron Therapeutics, Inc. (HRTX) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Heron Therapeutics, Inc. (HRTX).

Get it on Google Play Download on Google Play Download on the App Store Download on the App Store

Equity Details

Price & Market Data

Price: $0.85

Daily Change: -$0.0211 / 2.48%

Daily Range: $0.85 - $0.903

Market Cap: $162,553,120

Daily Volume: 1,049,775

Performance Metrics

1 Week: -6.35%

1 Month: -16.26%

3 Months: -27.42%

6 Months: -15.45%

1 Year: -53.43%

YTD: -33.01%

About Heron Therapeutics, Inc. (HRTX)

Full market details for Heron Therapeutics, Inc. (HRTX). Current price: 0.85, daily change: -$0.0211 / 2.48%. Market cap: 162,553,120. Comprehensive performance data across all periods.

Company Details

Employees: 128

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.

Selected stocks

Toro Corp. (TORO)

Cheetah Net Supply Chain Service Inc. (CTNT)

Playboy, Inc. (PLBY)

CNS Pharmaceuticals, Inc. (CNSP)

Tantech Holdings Ltd. (TANH)